LifeSci Advisors
Contributor since: 2011
Company: LifeSci Advisors
Latest Articles
Investing In The Upcoming Biosimilars Revolution
BioCryst: The Next Orphan Drug $1B+ Company
Acthar Gel Outperforms Methylprednisolone In Head-To-Head Study In MS Patients
Questcor: Results Of Rheumatology Physician Survey Show Strong Uptake Of Acthar
Upcoming Orphan Drug Approval Decisions For 4 Biopharma Companies
Important Catalysts For 3 Biotech Companies
What Is Next For Transcept Pharmaceuticals After Disappointing Intermezzo Launch?
Upcoming Catalysts For 4 Biotech Stocks
New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 3
Prostate Cancer Market Takes Shape - Part 2: Treatments In Clinical Development
Infinity Pharmaceuticals: Completion Of Phase I/II Trials May Drive Stock
New Second Generation Combination Therapy For HCV - First Or Best In The Market - Part 2
New Second Generation Combination Therapy For HCV - First Or Best In The Market (Part 1)
Prostate Cancer Market Takes Shape - Part 1: Dendreon And Medivation
Threshold, Clovis and Celgene: An Update On Pancreatic Cancer Trials
Biotech Catalyst Calendar - 4 Stocks To Watch In November
Sarepta Part II: Commercial Potential Of Eteplirsen In The Next Hot Market For Orphan Drug
Avanir Pharmaceuticals: Pipeline Overview And Stock Valuation
Aegerion's Lomitapide - FDA Approval, Strong Launch, Stock Price Increase Anticipated
Sarepta Part I: The Possibility Of An Accelerated Approval Of Eteplirsen
Questcor: Results Of Our Physician Survey Suggest Increased Sales For Acthar Gel
Questcor: What's Really Changed?
Ariad Pharmaceuticals: Ponatinib Approval Anticipated In Second-Line CML
Protalix Biotherapeutics: Eyes On Elelyso Sales And Advancing Pipeline
Dyax And ViroPharma: An Overview Of HAE Space
Questcor Poised To Rally To $80 On Continued Sales Growth
Ziopharm Oncology: Completion Of PICASSO 3 Clinical Trial Shows Promises For Driving Stock
Arena, Orexigen And Vivus: Obesity Sector Overview - Part 2
Arena Pharmaceuticals, Orexigen Therapeutics, And Vivus Therapeutics - Obesity Sector Overview - Part 1
Despite Legal And China Concerns, Prospects Are Strong For SciClone Pharmaceuticals
AcelRx Pharmaceuticals: Next Generation Of Pain Management Technologies
Survey Of Surgeons Indicates Strong Launch For Exparel